Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320
Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $340 to $320.
Stocks · News reference
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $253
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $256 to $253.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
argenx announced positive phase II results for FB102, an investigational therapy for celiac disease, meeting its primary endpoint with significant improvements in intestinal tissue measures versus placebo and no new safety signals. The company plans to advance FB102 into late-stage development and evaluate it for other autoimmune conditions. However, the stock declined nearly 12% following a separate announcement that argenx discontinued its phase III UNITY study for Vyvgart Hytrulo in Sjögren's disease.
RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345
RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $350 to $345.